Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Subcutaneous injection offers the potential for a faster, more convenient alternative to intravenous infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received ...
Rockville, Md.—The Association for Research in Vision and Ophthalmology (ARVO) Foundation congratulates Diana C. Lozano, PhD, who was awarded the 2024 Genente
The Red Biotechnology Market Size accounted for USD 360.3 Billion in 2022 and is estimated to achieve a market size of USD 656.1 Billion by 2032 growing at a CAGR of 6.3% from 2023 to 2032.
Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion in cash, cash...